Prophylaxe der kaninen Parvovirose

Michèle Bergmann; Monika Freisl; Katrin Hartmann

doi:10.1055/a-1402-9476

Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, Table of Contents

Tierarztl Prax Ausg K Kleintiere Heimtiere 2021; 49(02): 122-125
DOI: 10.1055/a-1402-9476

Übersichtsartikel

Prophylaxe der kaninen Parvovirose

Teil 2: ImpfstoffeProphylaxis of canine parvovirosisPart 2: Vaccines

Authors

Michèle Bergmann

Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
Monika Freisl

Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
Katrin Hartmann

Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München

Abstract

Zusammenfassung

Die Impfung ist die wichtigste Maßnahme zum Schutz vor kaniner Parvovirose. Daher zählt die Impfung gegen das kanine Parvovirus (CPV) zu den Core-Komponenten der Hundeimpfung. Modifizierte Lebendvakzinen (MLV) haben sich als sehr wirksam und zugleich sicher erwiesen. Sie bieten einen zuverlässigen Schutz, der bereits nach wenigen Tagen eintritt und viele Jahre anhält. MLV enthalten keine Adjuvanzien; sie sind hinsichtlich ihres allergenen und toxischen Potenzials Impfstoffen mit inaktiviertem CPV in aller Regel überlegen. Aus diesen Gründen werden MLV Impfstoffen aus inaktivierten Viren vorgezogen. In Deutschland und in den meisten anderen Ländern Europas sind heute ausschließlich MLV auf dem Markt verfügbar. Sie enthalten attenuiertes CPV-2 oder (seltener) CPV-2b und bieten einen kreuzprotektiven Schutz gegen die für den Hund im Feld relevanten Varianten CPV-2a, -2b, -2c. Wiederholungsimpfungen bei adulten Hunden mit MLV sollten frühestens alle 3 Jahre oder in längeren Intervallen (nach Bedarf bei fehlenden Antikörpern) durchgeführt werden. Dies gilt selbst dann, wenn der verwendete Impfstoff nur für eine 1- oder 2-Jahres-Intervall zugelassen ist. MLV-Produkte werden zur Impfung gesunder Hunde ab der 4. bis 6. Lebenswoche empfohlen. Ein Nachteil von MLV besteht in einer potenziellen Interferenz mit der Parvovirosediagnostik.

Abstract

Vaccination is still the most effective measure to prevent canine parvovirosis. Therefore, vaccines against canine parvovirus (CPV) infection are considered core vaccines. Modified life vaccines (MLV) have been proven to be very effective and safe, since they are characterized by early onset (within a few days after vaccination) and long duration of immunity (several years). MLV do not contain adjuvants; they are also advantageous in terms of possessing less allergenic and toxic properties. Therefore, MLV are widely used as first line vaccines. In Germany and in most other European countries, only MLV are available on the market. MLV contain CPV-2 or (less often) CPV-2b and offer cross-protection against the variants CPV-2a, -2b, -2c that are relevant for dogs in the field. Revaccination with MLV should be performed in 3-year-intervals or longer intervals (only in case of lacking antibodies) even if the licensed MLV is registered for re-vaccination intervals of 1 or 2 years. MLV should only be administered to healthy dogs older than 4 to 6 weeks of age. A possible disadvantage of MLV is its interference with the diagnosis of a CPV infection.

Schlüsselwörter

CPV - Hund - Schutz - Immunität - Impfung - Vakzine - MLV

Key words

CPV - dog - protection - immunity - vaccination - vaccine - MLV

Full Text

References

Literatur
1 Schultz RD. Current and future canine and feline vaccination programs. Vet Med 1998; 93: 233-254
2 StIKo Vet am FLI. Leitlinie zur Impfung von Kleintieren. 5. Aufl.. 2021 https://www.tieraerzteverband.de/bpt/berufspolitik/Impfkommission/stiko-vet_empfehlungen-mitteilungen.php Stand: 15.03.2021.
3 Day MJ, Horzinek MC, Schultz RD. et al. WSAVA Guidelines for the vaccination of dogs and cats. J Small Anim Pract 2016; 57: E1-E45
4 Ford RB, Larson LJ, McClure KD. et al. 2017 AAHA Canine Vaccination Guidelines. J Am Anim Hosp Assoc 2017; 53: 243-251
5 Kelman M, Ward MP, Barrs VR. et al. The geographic distribution and financial impact of canine parvovirus in Australia. Transbound Emerg Dis 2019; 66: 299-311
6 Paul MA, Appel M, Barrett R. et al. Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force: executive summary and 2003 canine vaccine guidelines and recommendations. J Am Anim Hosp Assoc 2003; 39: 119-131
7 Paul MA, Carmichael LE, Childers H. et al. 2006 AAHA canine vaccine guidelines. J Am Anim Hosp Assoc 2006; 42: 80-89
8 Welborn LV, DeVries JG, Ford R. et al. 2011 AAHA canine vaccination guidelines. J Am Anim Hosp Assoc 2011; 47: 1-42
9 Day MJ. Immune system development in the dog and cat. J Comp Pathol 2007; 137: S10-15
10 StIKo Vet am FLI. Stellungnahme zur Impfung von immunsupprimierten und alten Patienten in der Kleintierpraxis. 2017: 1-15
11 StIKo Vet am FLI. Stellungnahme zur Impfung nach Antikörperbestimmung bei Hund und Katze. 2017: 1-9
12 StIKo Vet am FLI. Empfehlungen zur guten Impfpraxis in der Veterinärmedizin. 2018: 1-18
13 Johnson R, Spradbrow P. Isolation from dogs with severe enteritis of a parvovirus related to feline panleukopenia virus. Aust Vet J 2008; 55: 151-152
14 Hoelzer K, Parrish CR. The emergence of parvoviruses of carnivores. Vet Res 2010; 41: 39
15 Decaro N, Buonavoglia C. Canine parvovirus – a review of epidemiological and diagnostic aspects, with emphasis on type 2c. Vet Microbiol 2012; 155: 1-12
16 Clegg SR, Coyne KP, Dawson S. et al. Canine parvovirus in asymptomatic feline carriers. Vet Microbiol 2012; 157: 78-85
17 Parrish CR, Aquadro CF, Strassheim ML. et al. Rapid antigenic-type replacement and DNA sequence evolution of canine parvovirus. J Virol 1991; 65: 6544-6552
18 Parrish CR, O’Connell PH, Evermann JF. et al. Natural variation of canine parvovirus. Science 1985; 230: 1046-1048
19 Buonavoglia C, Martella V, Pratelli A. et al. Evidence for evolution of canine parvovirus type 2 in Italy. J Gen Virol 2001; 82: 3021-3025
20 Decaro N, Buonavoglia C. Canine parvovirus post-vaccination shedding: Interference with diagnostic assays and correlation with host immune status. Vet J 2017; 221: 23-24
21 Hernández-Blanco B, Catala-López F. Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies?: A systematic review of controlled clinical trials. Vet Microbiol 2015; 180: 1-9
22 Kapil S, Cooper E. Vaccines containing canine parvovirus genetic variants. In: The Board of Regents for Oklahoma State University, Whitehurst, Oklahoma State University, Oklahoma, USA. 2008 https://patentsgooglecom/patent/WO2008157236A1 Stand: 28.08.2019
23 Kapil S, Cooper E, Lamm C. et al. Canine parvovirus types 2c and 2b circulating in North American dogs in 2006 and 2007. J Clin Microbiol 2007; 45: 4044-4047
24 Lamm CG, Rezabek GB. Parvovirus infection in domestic companion animals. Vet Clin North Am Small Anim Pract 2008; 38: 837-850
25 Ling M, Norris JM, Kelman M. et al. Risk factors for death from canine parvoviral-related disease in Australia. Vet Microbiol 2012; 158: 280-290
26 Nandi S, Kumar M, Mohapatra TK. et al. Emergence of canine parvovirus – 2 variants and its impact on vaccination. World Appl Sci J 2013; 23: 1366-1376
27 Patel JR, Heldens JG. Review of companion animal viral diseases and immunoprophylaxis. Vaccine 2009; 27: 491-504
28 Truyen U. Evolution of canine parvovirus – a need for new vaccines?. Vet Microbiol 2006; 117: 9-13
29 Cavalli A, Martella V, Desario C. et al. Evaluation of the antigenic relationships among canine parvovirus type 2 variants. Clin Vaccine Immunol 2008; 15: 534-539
30 Kang BK, Song DS, Lee CS. et al. Prevalence and genetic characterization of canine parvoviruses in Korea. Virus Genes 2008; 36: 127-133
31 Ohshima T, Hisaka M, Kawakami K. et al. Chronological analysis of canine parvovirus type 2 isolates in Japan. J Vet Med Sci 2008; 70: 769-775
32 Pratelli A, Cavalli A, Martella V. et al. Canine parvovirus (CPV) vaccination: Comparison of neutralizing antibody responses in pups after inoculation with CPV2 or CPV2b modified live virus vaccine. Clin Diagn Lab Immunol 2001; 8: 612-615
33 Appel MJG, Carmichael LE. Can a commercial vaccine protect pups against a recent field isolate of parvovirus?. Vet Med 1987; 82: 1091-1094
34 Glover S, Anderson C, Piontkowski M. et al. Canine parvovirus (CPV) type 2b vaccine protects puppies with maternal antibodies to CPV when challenged with virulent CPV-2c virus. Int J Appl Res Vet Med 2012; 10: 217-224
35 Greenwood NM, Chalmers WS, Baxendale W. et al. Comparison of isolates of canine parvovirus by restriction enzyme analysis, and vaccine efficacy against field strains. Vet Rec 1995; 136: 63-67
36 Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?. Vet Ther 2008; 9: 94-101
37 Siedek EM, Schmidt H, Sture GH. et al. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c. Berl Munch Tierarztl Wochenschr 2011; 124: 58-64
38 Spibey N, Greenwood NM, Sutton D. et al. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol 2008; 128: 48-55
39 Von Reitzenstein M, Ludlow D, Marcos S. et al. Cross protection of vanguard 5L4-CV vaccine against virulent canine parvovirus-2c circulating in the USA. Int J Appl Res Vet M 2012; 10: 187-197
40 Wilson S, Illambas J, Siedek E. et al. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c. Vaccine 2014; 32: 5420-5424
41 Wilson S, Stirling C, Borowski S. et al. Vaccination of dogs with Duramune DAPPi + LC protects against pathogenic canine parvovirus type 2c challenge. Vet Rec 2013; 172: 662
42 Yule TD, Roth MB, Dreier K. et al. Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease. Vaccine 1997; 15: 720-729
43 Decaro N, Desario C, Elia G. et al. Evidence for immunisation failure in vaccinated adult dogs infected with canine parvovirus type 2c. New Microbiol 2008; 31: 125-130
44 Decaro N, Cirone F, Desario C. et al. Severe parvovirus in a 12-year-old dog that had been repeatedly vaccinated. Vet Rec 2009; 164: 593-595
45 Cavalli A, Bozzo G, Decaro N. et al. Characterization of a canine parvovirus strain isolated from an adult dog. New Microbiol 2001; 24: 239-242
46 Sutton D, Vinberg C, Gustafsson A. et al. Canine parvovirus type 2c identified from an outbreak of severe gastroenteritis in a litter in Sweden. Acta Vet Scand 2013; 55: 64
47 Miranda C, Thompson G. Canine parvovirus in vaccinated dogs: A field study. Vet Rec 2016; 178: 397
48 Mittal M, Chakravarti S, Mohapatra JK. et al. Molecular typing of canine parvovirus strains circulating from 2008 to 2012 in an organized kennel in India reveals the possibility of vaccination failure. Infect Genet Evol 2014; 23: 1-6
49 De Oliveira PSB, Cargnelutti JF, Masuda EK. et al. New variants of canine parvovirus in dogs in southern Brazil. Arch Virol 2019; 164: 1361-1369
50 Barrs VR. Feline Panleukopenia: A Re-emergent Disease. Vet Clin North Am Small Anim Pract 2019; 49: 651-670
51 Barrs VR. Cats at risk from deadly virus outbreak. https://www.sydney.edu.au/news-opinion/news/2017/02/08/cats-at-risk-from-deadly-virus-outbreak.html Stand: 15.03.2021
52 Siegrist CA. The challenges of vaccine responses in early life: Selected examples. J Comp Pathol 2007; 137: 4-9
53 Bergman JG, Muniz M, Sutton D. et al. Comparative trial of the canine parvovirus, canine distemper virus and canine adenovirus type 2 fractions of two commercially available modified live vaccines. Vet Rec 2006; 159: 733-736
54 Kanellos T, Robinson A, Chipanga P. et al. Vaccination of puppies at 7 and 10 weeks with a multivalent vaccine gives protective seroconversion. Congress of the World Small Animal Veterinary Association (WSAVA). Prag, Tschechische Republik. 2006 https://www.vin.com/apputil/content/defaultadv1.aspx?pId=11223&meta=generic&id=3859175 Stand: 15.03.2021
55 Kanellos T, Robinson AJ, Chipanga P. et al. Use of a MLV vaccine in 6 weeks old puppies with CPV MDAs prevents clinical disease. In: Congress of the World Small Animal Veterinary Association (WSAVA). Prag, Tschechische Republik. 2006 https://www.vin.com/apputil/content/defaultadv1.aspx?pId=11223&meta=generic&catId=31439&id=3859174&ind=3859421&objTypeID=3859117 Stand: 15.03.2021
56 Larson LJ, Schultz RD. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection. Am J Vet Res 1997; 58: 360-363
57 European Medicines Agency. Note for guidance: Field trials with veterinary vaccines, adopted guideline, reference number EMA/CVMP/852/99. 2001: 1-8 https://www.ema.europa.eu/en/field-trials-veterinary-vaccines Stand: 15.03.2021
58 Altman KD, Kelman M, Ward MP. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure?. Vet Microbiol 2017; 210: 8-16
59 Poulet H. Alternative early life vaccination programs for companion animals. J Comp Pathol 2007; 137: S67-71
60 Hoare CM, DeBouck P, Wiseman A. Immunogenicity of a low-passage, high-titer modified live canine parvovirus vaccine in pups with maternally derived antibodies. Vaccine 1997; 15: 273-275
61 Larson LJ, Schultz RD. High-titer canine parvovirus vaccine: Serologic response and challenge-of-immunity study. Vet Med 1996; 91: 210-218
62 Carmichael LE. Canine viral vaccines at a turning point – a personal perspective. In: Schultz RD. ed. Canine and feline vaccines. Advances in Veterinary Medicine, Vol. 41, Veterinary Vaccines and Diagnostics. San Diego, Kalifornien, USA: Academic Press; 1999: 289-307
63 Friedrich K, Truyen U. Untersuchung der Wirksamkeit von Parvovirusimpfstoffen und der Effektivität zweier Impfschemata. Prakt Tierarzt 2000; 81: 988-994
64 Greene CE, Levy J. Immunoprophylaxis. In: Greene CE. ed. Infectious Diseases of the Dog and Cat. 4th ed.. St. Louis, Missouri, USA: Saunders Elsevier; 2012: 1163-1205
65 O’Brien SE. Serologic response of pups to the low-passage, modified-live canine parvovirus-2 component in a combination vaccine. J Am Vet Med Assoc 1994; 204: 1207-1209
66 Burtonboy S, Charlier P, Hertoghs J. et al. Performance of high titre attenuated canine parvovirus vaccine in pups with maternally derived antibody. Vet Rec 1991; 128: 377-381
67 De Cramer KG, Stylianides E, van Vuuren M. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus. Vet Microbiol 2011; 149: 126-132
68 Hoskins JD. Performance of a new generation canine parvovirus vaccine in Rottweiler puppies. Canine Pract 1997; 22: 29-31
69 Larson LJ, Schultz RD. Closing the window of susceptibility. Top Vet Med 1996; 7: 22-26
70 Schultz RD, Larson LJ. The new generation of parvovirus vaccines. A comparison study. Compend Contin Educ Vet 1996; 18: 640-641
71 Schultz RD, Thiel B, Mukhtar E. et al. Age and long-term protective immunity in dogs and cats. J Comp Pathol 2010; 142: 102-108
72 Appel MJG. Forty years of canine vaccination. In: Schultz RD. ed. Canine and feline vaccines. Advances in Veterinary Medicine, Vol. 41, Veterinary Vaccines and Diagnostics. San Diego, Kalifornien, USA: Academic Press; 1999: 309-324
73 Veir JK, Duffy AL, Dow SW. et al. Comparison of quantitative PCR and conventional endpoint PCR for amplication of parvovirus DNA in blood from naturally infected and recently vaccinated dogs. ACVIM Forum & Canadian Veterinary Veterinary Medical Association Convention. Montréal, Québec, Kanada; 2009. J Vet Intern Med 2009; 2023: 2769
74 Freisl M, Speck S, Truyen U. et al. Faecal shedding of canine parvovirus after modified-live vaccination in healthy adult dogs. Vet J 2017; 219: 15-21
75 Day MJ, Schultz RD. Vaccination. In: Day MJ, Schultz RD. eds. Veterinary Immunology – Principles and Practice. 2nd ed.. Boca Raton, Florida, USA: CRC Press Taylor & Francis Group; 2014: 233-247
76 Ellis RW. New technologies for making vaccines. Vaccine 1999; 17: 1596-1604
77 MacLachlan NJ, Dubovi EJ, Barthold SW. et al. Antiviral immunity and virus vaccines. In: MacLachlan NJ, Dubovi EJ, Barthold SW. et al., ed. Fenner’s Veterinary Virology. 5th ed.. London, United Kingdom: Academic Press, Imprint of Elsevier; 2017: 79-104
78 Tizard IR. Vaccines and their production. In: Tizard IR. ed. Veterinary Immunology. 10th ed.. St. Louis, Missouri, USA: Elsevier; 2018: 261-273
79 Van Kampen KR. Recombinant vaccine technology in veterinary medicine. Vet Clin North Am Small Anim Pract 2001; 31: 535-538
80 Carmichael LE, Appel MJG, McGregor DD. Modified living canine parvovirus vaccine. 1981 https://patentsgooglecom/patent/WO1981002978A1 Stand: 28.08.2019
81 Carmichael LE, Joubert JC, Pollock RV. A modified live canine parvovirus strain with novel plaque characteristics. I. Viral attenuation and dog response. Cornell Vet 1981; 71: 408-427
82 McGavin DR, Lavidis L. Attenuated canine parvovirus (CPV), vaccine comprising CPV and method of preventing infection by CPV in dogs. 1991 http://europepmc.org/article/PAT/EP0485463 Stand: 22.02.2021
83 Parrish CR, Aquadro CF, Carmichael LE. Canine host range and a specific epitope map along with variant sequences in the capsid protein gene of canine parvovirus and related feline, mink, and raccoon parvoviruses. Virology 1988; 166: 293-307
84 Parrish CR, Gruenberg A, Carmichael LE. Attenuated canine parvovirus vaccine. 1996 http://europepmc.org/article/PAT/WO9614088 Stand: 24.02.2021
85 Dodds WJ. The immune system and disease resistance. Clin Tech in Small Anim Pract 2002; 17: 58-63
86 European Advisory Board on Cat Diseases ABCD. Vaccines and vaccination, an introduction. 2015 http://www.abcdcatsvets.org/vaccines-and-vaccination-an-introduction Stand: 24.02.2021
87 Tizard I. Risks associated with use of live vaccines. J Am Vet Med Assoc 1990; 196: 1851-1858
88 Schwanig M, Löwer J. Herstellung und Prüfung von Impfstoffen. In: Spiess H, Heininger U. Hrsg. Impfkompendium. 6. Aufl.. Stuttgart: Thieme; 2005: 24-37
89 Roth JA. Mechanistic bases for adverse vaccine reactions and vaccine failures. In: Schultz RD. ed. Adverse vaccine reactions, failures, and postmarketing surveillance. Advances in Veterinary Medicine, Vol. 41, Veterinary Vaccines and Diagnostics. San Diego, Kalifornien, USA: Academic Press; 1999: 681-700
90 Van Oirschot JT. Classical attenuated vaccines. In: Pastoret PP, Blancou J, Vannier P. et al., eds. Categories of products mechanism of action, advantages/disadvantages. Veterinary Vaccinology. Amsterdam, Niederlande: Elsevier; 1997: 260-262
91 Desmettre P, Martinod S. Conception of a vaccine. In: Pastoret PP, Blancou J, Vannier P. et al., eds. Research and development. Veterinary Vaccinology. Amsterdam, Niederlande: Elsevier Science B. V.; 1997: 176-178
92 Horzinek MC, Schijns VECJ, Denis M. et al. Applications of vaccines. In: Pastoret PP, Blancou J, Vannier P. et al., eds. General description of vaccines. Veterinary Vaccinology. Amsterdam, Niederlande: Elsevier; 1997: 135-136
93 Kreth HW. Immunität und Schutzimpfungen. In: Spiess H, Heininger U. Hrsg. Impfkompendium. 6. Aufl.. Stuttgart: Thieme; 2005: 9-23
94 Schultz RD. Duration of immunity to canine vaccines: What we know and don’t know. In: Canine Infectious Disease Workshop: From Clinics to Molecular Pathogenesis. Ithaca, New York., USA: James A. Baker Institute, Cornell University; 1999. www.ivis.org/proceedings/Baker_Can_Inf_Dis/ Stand: 28.04.2019
95 Schultz RD. Duration of immunity for canine and feline vaccines: A review. Vet Microbiol 2006; 117: 75-79
96 Olson P, Hedhammar A, Klingeborn B. Canine parvovirus infection, canine distemper and infectious canine hepatitis: Inclination to vaccinate and antibody response in the Swedish dog population. Acta Vet Scand 1996; 37: 433-443
97 Killey R, Mynors C, Pearce R. et al. Long-lived immunity to canine core vaccine antigens in UK dogs as assessed by an in-practice test kit. J Small Anim Pract 2018; 59: 27-31
98 Ford RB. Vaccines and vaccinations. The strategic issues. Vet Clin North Am Small Anim Pract 2001; 31: 439-453
99 Greene CE, Schultz RD, Ford RB. Canine vaccination. Vet Clin North Am Small Anim Pract 2001; 31: 473-492
100 Horzinek MC, Schijns VECJ, Denis M. et al. Categories of vaccines. In: Pastoret PP, Blancou J, Vannier P. et al., eds. General description of vaccines. Veterinary Vaccinology. Amsterdam, Niederlande: Elsevier; 1997: 132-135
101 Martinod S. Adverse effects of vaccination. In: Pastoret PP, Blancou J, Vannier P. et al., eds. Technical Basis of Vaccination. Veterinary Vaccinology. Amsterdam, Niederlande: Elsevier; 1997: 574-580
102 Povey RC, Carman PS. Risks of vaccination. In: Pastoret PP, Blancou J, Vannier P. et al., eds. Technical Basis of Vaccination. Veterinary Vaccinology. Amsterdam, Niederlande: Elsevier; 1997: 546-551
103 Meyer EK. Vaccine-associated adverse events. Vet Clin North Am Small Anim Pract 2001; 31: 493-514
104 Krakowka S, Olsen RG, Axthelm MK. et al. Canine parvovirus infection potentiates canine distemper encephalitis attributable to modified live-virus vaccine. J Am Vet Med Assoc 1982; 180: 137-139
105 Whetstone CA, Bunn TO, Emmons RW. et al. Use of monoclonal antibodies to confirm vaccine-induced rabies in ten dogs, two cats, and one fox. J Am Vet Med Assoc 1984; 185: 285-288
106 Cornwell HJ, Thompson H, McCandlish IA. et al. Encephalitis in dogs associated with a batch of canine distemper (Rockborn) vaccine. Vet Rec 1988; 122: 54-59
107 Gloyd J. Distemper vaccines recalled. J Am Vet Med Assoc 1995; 207: 1397
108 Bergmann M, Freisl M, Hartmann K. et al. Antibody Response to Canine Parvovirus Vaccination in Dogs with Hyperadrenocorticism Treated with Trilostane. Vaccines 2020; 8: 547
109 Decaro N, Desario C, Elia G. et al. Occurrence of severe gastroenteritis in pups after canine parvovirus vaccine administration: A clinical and laboratory diagnostic dilemma. Vaccine 2007; 25: 1161-1166
110 Robert-Koch-Institut. Ist es ratsam, in der Inkubationsphase einer impfpräventablen Erkrankung zu impfen?. 2012 https://www.rki.de/SharedDocs/FAQ/Impfen/AllgFr_Kontraindi/faq_impfen_Kontraindi_ges.html Stand: 24.02.2021
111 Hayes MA, Russell RG, Babiuk LA. Sudden death in young dogs with myocarditis caused by parvovirus. J Am Vet Med Assoc 1979; 174: 1197-1203
112 Povey RC, Carman PS. Factors influencing the outcome of vaccination. In: Pastoret PP, Blancou J, Vannier P. et al., eds. Technical basis of vaccination. Veterinary Vaccinology. Amsterdam, Niederlande: Elsevier; 1997: 540-545
113 Hustead DR. What you can and cannot learn from reading a vaccine label. Vet Clin North Am Small Anim Pract 2001; 31: 539-556
114 Halbrooks RD, Swango LJ, Schnurrenberger PR. et al. Response of gray foxes to modified live-virus canine distemper vaccines. J Am Vet Med Assoc 1981; 179: 1170-1174
115 Durchfeld B, Baumgärtner W, Herbst W. et al. Vaccine-associated canine distemper infection in a litter of African hunting dogs (Lycaon pictus). Zentralbl Veterinaermed B 1990; 37: 203-212
116 Carpenter JW, Appel MJ, Erickson RC. et al. Fatal vaccine-induced canine distemper virus infection in black-footed ferrets. J Am Vet Med Assoc 1976; 169: 961-964
117 Kazacos KR, Thacker HL, Shivaprasad HL. et al. Vaccination-induced distemper in kinkajous. J Am Vet Med Assoc 1981; 179: 1166-1169
118 Bush M, Montali RJ, Brownstein D. et al. Vaccine-induced canine distemper in a lesser panda. J Am Vet Med Assoc 1976; 169: 959-960
119 Buonavoglia C, Cavalli A, Tempesta M. et al. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose. New Microbiol 1995; 18: 371-375
120 Cavalli A, Desario C, Marinaro M. et al. Oral administration of modified live canine parvovirus type 2b induces systemic immune response. Vaccine 2020; 38: 115-118
121 Martella V, Cavalli A, Decaro N. et al. Immunogenicity of an intranasally administered modified live canine parvovirus type 2b vaccine in pups with maternally derived antibodies. Clin Diagn Lab Immunol 2005; 12: 1243-1245
122 Carmichael LE, Pollock RV, Joubert JC. Response of puppies to canine-origin parvovirus vaccines. Mod Vet Practic 1984; 65: 99-102
123 Decaro N, Crescenzo G, Desario C. et al. Long-term viremia and fecal shedding in pups after modified-live canine parvovirus vaccination. Vaccine 2014; 32: 3850-3853
124 Goddard A, Leisewitz AL. Canine parvovirus. Vet Clin North Am Small Anim Pract 2010; 40: 1041-1053
125 Macintire DK, Smith-Carr S. Canine parvovirus. Part II. Clinical signs, diagnosis, and treatment. Compend Contin Educ Vet 1997; 19: 219-302
126 Prittie J. Canine parvoviral enteritis: A review of diagnosis, management, and prevention. J Vet Emerg Crit Care 2004; 14: 167-176
127 Sykes JE. Canine parvovirus infections and other viral enteritides. In: Sykes JE. ed. Canine and Feline Infectious Diseases. 1st ed.. St. Louis, Missouri, USA: Elsevier Saunders; 2014: 141-151
128 Sykes JE. Immunization. In: Sykes JE. ed. Canine and Feline Infectious Diseases. 1st ed.. St. Louis, Missouri, USA: Elsevier Saunders; 2014: 119-130
129 Greene CE, Decaro N. Canine viral enteritis. In: Greene CE. ed. Infectious Diseases of the Dog and Cat. 4th ed.. St. Louis, Missouri, USA: Elsevier Saunders; 2012: 67-75
130 Patterson EV, Reese MJ, Tucker SJ. et al. Effect of vaccination on parvovirus antigen testing in kittens. J Am Vet Med Assoc 2007; 230: 359-363
131 Pollock RV, Carmichael LE. Canine viral enteritis. Vet Clin North Am Small Anim Pract 1983; 13: 551-566
132 Pollock RV, Coyne MJ. Canine parvovirus. Vet Clin North Am Small Anim Pract 1993; 23: 555-568
133 McCandlish IA, Cornwell HJ, Thompson H. et al. Distemper encephalitis in pups after vaccination of the dam. Vet Rec 1992; 130: 27-30
134 Truyen U, Geissler K, Parrish CR. et al. No evidence for a role of modified live virus vaccines in the emergence of canine parvovirus. J Gen Virol 1998; 79: 1153-1158
135 Tizard IR. The use of vaccines. In: Tizard IR. ed. Veterinary Immunology. 10th ed.. St. Louis, Missouri, USA: Elsevier; 2018: 274-284
136 Eugster AK. Studies on canine parvovirus infections: Development of an inactivated vaccine. Am J Vet Res 1980; 41: 2020-2024
137 Pollock RV, Carmichael LE. Dog response to inactivated canine parvovirus and feline panleukopenia virus vaccines. Cornell Vet 1982; 72: 16-35
138 Povey RC, Carman PS, Ewert E. The duration of immunity to an inactivated adjuvanted canine parvovirus vaccine. A 52 and 64 week postvaccination challenge study. Can Vet J 1983; 24: 245-248
139 Wallace BL, McMillen JK. An inactivated canine parvovirus vaccine: Duration of immunity and effectiveness in presence of maternal antibody. Canine Pract 1985; 12: 14-19

Supplementary Material

Supplementary material (PDF) (opens in new window)